Derbyshire Medicines Management and Clinical Policies
NICE TA241: Leukaemia (chronic myeloid): Nirlotinib – recommended for Philadelphia-chromosome-positive CML if standard dose imatinib unsuccessful or unsuitable.
NICE TA251: Leukaemia (chronic myeloid): For first-line treatment of chronic phase Philadelphia-chromosome-positive CML. Nirlotinib – recommended as an option only under a patient access scheme
